Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effects of ZFA-demethylase chimeras in vivo

ABSTRACT: Effects of ZFA-demethylase chimeras in vivo

PROVIDER: PRJNA1235647 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Effects of dCas9-demethylase chimeras in vivo

Project description:Effects of dCas9-demethylase chimeras in vivo

| PRJNA1235646 | ENA

Effects of ZFA-demethylase chimeras in vivo

Project description:Gene expression profiling of transcriptional response to interferon stimulation after zinc finger -based demethylases.

2025-07-16 | GSE291857 | GEO

Effects of dCas9-demethylase chimeras in vivo

Project description:Gene expression profiling of transcriptional response to interferon stimulation after dCas9/gRNA -based demethylases.

2025-07-16 | GSE291856 | GEO

Preclinical targeted therapy for retinoblastoma using EpCAM Aptamer siRNA chimeras

Project description:siRNAs have played a major role in cancer drug discovery, but their potential is hampered due to off-target effects. Thus, delivery systems like RNA aptamers have been used to enhance the specific delivery of these siRNAs to cancer stem cells. We report the efficacy of three different EpCAM aptamer siRNA chimeras, which were investigated both in vitro and in vivo for their ability to reduce cancer cell progression. Using these chimeras, we demonstrated specific gene knockdown in EpCAM positive cells which ultimately led to the apoptosis. To study the efficacy of these aptamer chimeras in vivo, retinoblastoma xenografts bearing NCC Rb C 51 cells were created for the first time. Systemic administration of these aptamer chimeras reduced tumour growth to about 50%. We further investigated the central Role of PLK1 in Cancer Progression and demonstrated the anti-cancer effects of targeted EpCAM siPLK1 approach. Using SILAC-Mass spectrometry analysis, we showed that silencing PLK 1 gene can lead to p53 mediated cell cycle arrest. Thus, we establish EpCAM-siRNA chimeras as potential markers for targeted anti-cancer applications, which paves a platform for efficient second line of therapies in addition to existing chemotherapy options.

2022-03-02 | PXD008221 | Pride

Expression data from Tregs purified from WT-CD3KO or IIKO-CD3KO chimeras

Project description:Disruption of TCR /MHC class II interactions leads rapidly to alterations of the common CD4 Treg transcriptional signature Self-deprived, non-functional Tregs were compare to fully functional Tregs by microarrays. CD3ε-/- mice were lethally irradiated and their immune system reconstituted with WT mouse (WT-CD3KO chimeras) or IIKO mouse (IIKO-CD3KO) Bone Marrow cells. Twenty eight days later, peripheral Tregs from these chimeras were purified for RNA extraction and hybridization on Affymetrix microarrays.

2011-02-09 | E-GEOD-27151 | biostudies-arrayexpress

Effects of COP1 deletion in microglia in vivo

Project description:Effects of COP1 deletion in microglia in vivo

| PRJNA607242 | ENA

CpG islands recruit a histone H3 lysine 36 demethylase

Project description:This SuperSeries is composed of the following subset Series: GSE18588: CpG islands recruit a histone H3 lysine 36 demethylase [Illumina sequencing data] GSE21201: CpG islands recruit a histone H3 lysine 36 demethylase [Agilent data] Refer to individual Series

2010-04-26 | E-GEOD-21202 | biostudies-arrayexpress

Transcriptome analysis of zebrafish, medaka and zebraka chimeras

Project description:Transcriptome analysis of zebrafish, medaka and zebraka chimeras

| PRJNA630877 | ENA

Bioresponsive lysosome-targeting chimeras for targeted protein degradation

Project description:Bioresponsive lysosome-targeting chimeras for targeted protein degradation

| PRJNA1256450 | ENA

H3K4me3 associated chromatin by CUT&RUN on c-kit+ cells from chimeras

Project description:Sequencing of chromatin associated with H3K4me3 histone marks in live c-kit+ cells isolated by CUT&RUN from chimeras after transplantation with Ctrl-BM, MSC-BM and CpG-BM.

2023-03-24 | GSE199338 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data